The leader in utilizing high-throughput microfluidics for cell therapy development and manufacturing
About BendBio
The foundation of our approach – inertial microfluidics for gentle, high throughput cell processing – is exclusively licensed from Massachusetts General Hospital, the largest teaching hospital of Harvard Medical School, and is based on seminal and groundbreaking academic and clinical research.
BendBio is partnering with cell therapy developers and solution providers to integrate its technology and product offerings into discovery, development, and clinical manufacturing workflows.